Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc. completes enrollment in the biomarker-enriched patient cohort of its Phase 2 study of fadraciclib, a CDK2/9 inhibitor, targeting advanced solid tumors and lymphoma. This cohort focuses on patients with CDKN2A and/or CDKN2B abnormalities. An update will be presented at ENA 2024. Learn more: https://bit.ly/47GNMUs EORTC - European Organisation for Research and Treatment of Cancer, American Association for Cancer Research, National Cancer Institute (NCI) #ENASymp24 #Oncology #CancerResearch

Fadraciclib is a novel drug that targets and blocks two enzymes called CDK2 and CDK9. Why is this important? For more, please visit: https://bit.ly/4gfCZ7K #Biotech #CancerTreatment #Endometrial #OvarianCancer

Did you know that colorectal cancer (CRC) is the third most common type of cancer among adults in the United States? Given the heterogeneous nature of the disease and limited treatment options, there is a critical need for new therapies. Cyclacel's Fadraciclib, a highly selective CDK2/9 inhibitor, has shown promising preclinical results in treating advanced CRC. Learn more about how we are advancing treatment options: https://bit.ly/3YliEaC #CancerResearch #ColonCanter #RectalCancer #ColorectalCancer

Fadraciclib (formerly CYC065) from Cyclacel Pharmaceuticals, Inc. is a highly selective and potent CDK2/9 inhibitor, currently being evaluated in clinical trials for solid tumors and lymphoma. By inhibiting CDK2 and CDK9 fadraciclib causes apoptotic death through anaphase catastrophe of cancer cells at sub-micromolar concentrations. The study is currently enrolling the biomarker cohort for patients prospectively selected for CDKN2A/CDKN2B alterations and the T-cell lymphoma. cohort. Explore more about the potential of Fadraciclib: https://bit.ly/4gfCZ7K #CancerResearch #Biotech #HealthcareInnovation

Cyclacel Pharmaceuticals announces its participation at the 26th Annual H.C. Wainwright & Co., LLC Global Investment Conference from September 9-11, at the Lotte New York Palace Hotel. President & CEO Spiro Rombotis will represent the company. Attendees can access the presentation on-demand starting on September 9 at 7:00 AM ET at https://bit.ly/3SnAuG5 For more: https://bit.ly/3Z5BhzA #InvestorRelations #InvestmentConference #Biopharma

Cyclacel Pharmaceutical’s pipeline is dedicated to providing safe and effective oral anticancer treatments. Our two leading programs include Fadraciclib, a CDK2/9 inhibitor, and Plogosertib, a PLK1 inhibitor, are both currently in clinical development. Our mission is to expand treatment options for cancer patients globally. Discover more about our promising pipeline at https://bit.ly/3XcGRh8 #CancerResearch #Biotech #CancerTreatment #HealthcareInnovation

Join Spiro Rombotis, CEO of Cyclacel Pharmaceuticals, Inc., on the latest episode of the Oncology Overdrive podcast hosted by Shikha Jain, MD., dives into discussions about breakthroughs in drug development, the role of technology in biotech, and the future of epigenetics and precision oncology. 🧬🔬 Listen now for insightful revelations on the evolution of cancer treatment and how AI is shaping the landscape.🎧 https://bit.ly/3AI4wOO Healio | HemOnc Today #CancerResearch #Biotech

Cyclacel Pharmaceuticals, Inc. presented clinical, pharmacokinetic (PK), and pharmacodynamic (PD) data from the Phase 1 dose escalation cohort of the CYC065-101 study evaluating oral Fadraciclib at the 2024 ASCO Annual Meeting. The data demonstrated good tolerability and promising clinical activity, particularly in patients with CDKN2A/B loss or T-cell lymphoma. Learn more: https://bit.ly/3Mih69Q #CancerResearch #Biotech #ClinicalTrials #ASCO24

Today Cyclacel Pharmaceuticals, Inc. reported Q2 2024 financial results and is providing a business update via conference call and webcast at 4:30 PM EDT. The Phase 2 study of Fadraciclib, particularly in precision medicine cohorts, continues enrollment following our data release at ASCO 2024. For more, please visit: https://lnkd.in/edD5dSgP #InvestorRelations #Earnings #Finance #Biotech

Did you know that Plogosertib has demonstrated impressive efficacy in human tumor xenografts at nontoxic doses? Our translational biology program supports its development in leukemias and solid tumors. Recent data suggests PLK1 inhibition may be particularly effective in KRAS-mutated metastatic colorectal cancer. Learn more about Plogosertib’s potential at https://bit.ly/3WUGJ6P #CancerResearch #Biotech #Innovation